Urinary Detection Times and Excretion Profiles of Clonazepam and 7‐Aminoclonazepam After a Single Oral Dose
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Clonazepam (CLO) is a widely prescribed benzodiazepine also commonly encountered in forensic casework. However, the urinary excretion patterns of CLO and 7‐amino‐clonazepam (7‐amino‐CLO) have not been fully characterized in humans, warranting further investigation to improve interpretation of forensic toxicological findings. The main objectives of this study were to validate a UHPLC–MS/MS method to quantitate CLO and 7‐amino‐CLO in urine, and characterize urinary excretion profiles and detection windows of these analytes following controlled dosing. Volunteers ( n = 18) received a single oral dose of either 0.5 or 2.0 mg of Iktorivil, with urine samples collected pre‐dose, at 2, 4, 6, 8, 10, 12, 14, and 24 h on Day 1, and once daily on Days 2–6, 10, and 14 (i.e., 48, 72, 96, 120, 144, 240, 336 h post‐dose). The UHPLC–MS/MS method achieved a sensitive lower limit of quantitation (0.25 μg/L) and met all validation acceptance criteria. Mean creatinine‐corrected C max for the 0.5‐mg group were 4.8 ± 0.9 ng/mg for CLO and 31.0 ± 2.3 ng/mg for 7‐amino‐CLO, compared with 16.1 ± 3.0 ng/mg and 114.4 ± 13.6 ng/mg, respectively, for the 2.0‐mg group. Detection times for 7‐amino‐CLO were approximately three to four times longer than CLO for both groups. Immunoassay failed to detect all low‐dose cases, even with measurable 7‐amino‐CLO. These findings demonstrate the limitations of immunoassays for detecting low‐dose CLO exposure and underscore the importance of targeted testing (i.e., GC–MS/LC–MS) for CLO and 7‐amino‐CLO in drug‐facilitated crime investigations when CLO exposure is suspected, regardless of the immunoassay result.
Source: Drug Testing and Analysis
DOI: 10.1002/dta.70197
Language: English
Subfield: Toxicology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,440
OpenAlex ID: W7236676926
